Source: CureToday articles
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.
Recent Content
- Understanding the Use of Bispecific Antibodies in Multiple Myeloma
- Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds
- Overcoming Challenges and Advancing CAR-T Therapy for Myeloma
- LY6E as a new prognostic biomarker of multiple myeloma-related bone disease
- Dynamic monitoring of M-protein quantification by immunotyping using capillary zone electrophoresis during the chemotherapy of patients with multiple myeloma
- Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis
- Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
- Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
- Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis